Align Technology Inc Investor Event Transcript, Nov 17, 2026
Align Technology Inc (ALGN)
Align Technology CEO Joe Hogan is handing over to incoming CEO Jennifer Davis, with the transition finishing through December. The lowered guidance was mainly due to iTero pricing, discounts and mix rather than volume, and the installed base is up double digits. Management has talked about a 100 basis point improvement for next year, and China's VBP is a small second-half factor. AI summary
Conference Transcript - ALGN 2026-11-17
Mike Sarkone, Analyst — Jefferies
Okay, good morning, and welcome to the Jeffries Global Healthcare Conference in London. My name is Mike Sarkone. I'm an analyst on the U.S. Medical Supplies and Devices team at Jeffries, and this is a session for Align Technologies. Up on the dais with us, we have Joe Hogan, CEO, and John Marici, CFO, and also joined in the room is Jennifer Davis, incoming CEO, and Shirley Stacey, head of IR. So thank you very much for joining us today, gentlemen.
John Morici, CFO
Of course.
Mike Sarkone, Analyst — Jefferies
I guess just to kick off, Joe, a few weeks ago in conjunction with 3Q results that you reported, you announced your planned succession and retirement, so maybe we were hoping you could comment on the timing and the announcement and then just give us your thoughts on the positioning of the company as you hand over the reins.
Joseph Hogan, CEO
Yeah, I've been with ABB for 11 years now. I'm sorry, ABB. I left ABB to join a line 11 years ago. And 11 years, I think, is long enough. I'm approaching at 69 years old. I'm approaching 70 years old in May next year. And I think it was time for me to stand back from the business and also take another look at life. And so we've had a really good process internally in the sense of looking at candidates over a year, year and a half period. And Jennifer turned out just a terrific candidate for the job, and I couldn't be more excited about turning over the role of Jennifer. And she has a terrific background for us from her P&G time together. And so we've been beginning this transition over the last couple months, and we'll finish it through December. And I feel really good about the status of the business and Jen's ability to take it over.
Mike Sarkone, Analyst — Jefferies
Okay, great. Well, yeah, we wish you the best. It's been great working with you, and we're looking forward to working with Jennifer as well. I think it's maybe, you know... Shifting gears, touch on the macro a bit. On the 3Q call a few weeks ago, you mentioned or you characterized discretionary dental and ortho demand as challenged. Maybe you can elaborate more on what you're seeing and how it varies across region and channel.
Joseph Hogan, CEO
Yeah. I'd say nothing really changed in the third quarter from what we talked about before. Obviously, consumer demand is a big variable in our equation overall, and we know consumers are challenged. And our business is mostly out-of-pocket cost in that sense. But overall, we felt good about our performance in third quarter across the globe in different areas. You know, obviously, some products that we've announced recently, which are more, I think, viable from a consumer standpoint in lowering prices, like the NoAA product was a big help. You know, we had a real dichotomy between Invisalign sales, which did fairly well, versus Itero, which, you know, obviously year on year was down. But we did sell more units from an Itero standpoint, which lays a really good foundation for the business overall for growth in the future because we know more Itero placements will work. So I'd say overall no surprises in the third quarter, and I thought the team executed well. John, do you have anything to add?
John Morici, CFO
I mean, it's a similar environment that we've seen for a number of quarters now. And as Joe said, we want to do things in a tough environment to help with our doctors, you know, lower some of the upfront costs. And some of our technology and products are able to do that with the NOAA or even going a ways back to the 3 and 3, which was moving from the comprehensive unlimited to help with lowering the upfront cost. And then also helping with patient financing, doing a lot of things to try to connect that patient who might be reluctant to go into treatment. If there's things that we can do to get them into treatment with the financing and so on, we think that helps differentiate. And that's something that we've had to do for several quarters, and we're seeing good momentum around those two aspects.
Mike Sarkone, Analyst — Jefferies
Okay. That makes sense. I guess we're midway through calendar 4Q. Have you seen kind of relative stability versus what you saw in 3Q and any changes to note, I guess, as it relates to the macro?
Joseph Hogan, CEO
You know, when we made our forecast for 4Q, you know, it was based on we were already through the month of October. So our forecast pretty much reflects what we've seen between the two quarters.
Mike Sarkone, Analyst — Jefferies
And then, you know, on the aligner side, you lowered your 26 sales guide primarily due to the scan of revenues. You know, you just mentioned that. But it also included, we can call it a modest moderation in your outlook for aligner growth. I think it implies maybe aligner sales decelerate to about a low single-digit pace in 4Q. So I guess, can you just speak to kind of guidance construction and, I guess, what was incorporated in there?
John Morici, CFO
Yeah, as Joe said, we wanted to be able to include what we saw as we went through third quarter, what we saw starting fourth quarter, be prudent about our guidance so that we could reflect what the demand looks like, you know, not just in North America but across the globe, and that was a reflection of that. And as you said, the majority of adjustment was really due to iTero, and it's just, you know, not for lack of volume. The units have been great. Install base is up double digits, so we really feel good about the placement and what's happening with iTero. It's really around the pricing that we've seen, so some of the discounts that are needed to be able to get those placements. And then it's also around some of the mix that we have in iTero, and that's really the reflection that we've had with our guidance. But the rest of the business, really not a change from what we've seen in the past.
Mike Sarkone, Analyst — Jefferies
Okay, so, I mean, could you characterize at least, again, the modest downgrade in the outlook for aligner sales, more prudence and conservatism, or?
John Morici, CFO
Yeah, I think it's a reflection of what we see, and that gets into our guidance based on that prudence. You know, it's a challenging economy that we see, and we want to be able to reflect that in those markets.
Mike Sarkone, Analyst — Jefferies
And, you know, I guess last year there was kind of a brief blip where we talked about seeing a shift. Towards brackets and wires, right? Are you seeing anything like that taking place in the market?
Joseph Hogan, CEO
No, I wouldn't say there's any continuity. I mean, you'd see, you hear that at times and see that at times. Remember, we're, you know, roughly 75% adults and 25% teens. In general, you know, markets completely inverted to that, and mainly the wires and brackets. And so I feel, when you look at our phase one products, when you look at IPE and VisLine Palette Expander, VisLine First continues to do extremely And, obviously, we have some, you know, Class II devices like Mandibler Advancement. Really good progress in those areas, too. So, no, I'm not expecting a wires and brackets come back. They have, obviously, a good moat, you know, based on the orthodontic professionals that are out there. But I feel really good about the products that we have in that specific segment, both with, you know, more mature teen dentition but also primary dentition.
John Morici, CFO
And some of it's product related, too. So we have the no AA type products. That really helps win the gray area between some of those orthodontists on whether they use wires and brackets or maybe now the upfront cost is lower for them with the no AA product. So you start to see higher utilization. We've seen good doctor growth where our submitters have been up, and we saw a good quarter of that in the third quarter. And we saw North America ortho up as well. So there's going to be puts and takes as you go through. You know, sometimes there's more volume or not on wires and brackets and so on, but we feel like we're on the right track to make inroads.
Mike Sarkone, Analyst — Jefferies
Got it. And, you know, just as a quick follow-up to the zero AA, zero upfront cost, are you seeing that improve your ability to maybe gain back share?
John Morici, CFO
We definitely see winning doctors in the gray area. So you think about it, if they're going to stay up front and they're going to have wires and brackets, it might cost $200 or $300. A NOAA product, depending on their discount, might be $800, $850. And so, yes, it's still more than wires and brackets, but I think people understand the digital benefits that digital orthodontics, like what we provide, can give. So it helps win those gray areas, and you get more and more doctors to try. So when we've seen this pretty much now across the globe, I mean, our NOAA products are up triple digits on a year-over-year basis. So it is taking the adoption, and it's not just a mixed shift between other products. This is something that is seeing greater utilization, which we're pleased about. And it's also been able to help us maintain our ASPs because the way we recognize revenue, now we don't defer any revenue because there's no refinements that come later. So our ASPs on a year-to-date basis through October are about flat year over year. So it's really doing what we wanted it to do, and it really comes down to being able to have the technology to give to a doctor so that in one go they can finish treatment.
Joseph Hogan, CEO
There's been an evolution here, too, where orthos have been using our product for a number of years now, too. They don't need the five AA's or three AA's. They're very confident they see a case and say, I can do this in zero AA's or whatever. So it is a natural movement of confidence, and you see it less on the GP side, but much more on the ortho side. It's the assessed cases that do it, so we're excited about it. We think it's a good play for us.
Mike Sarkone, Analyst — Jefferies
Got it, and I guess kind of a reach question here. You know, as you exit the year, can you give us kind of a rough ballpark of, like, what percentage of your cases are comprised with the no AA now?
John Morici, CFO
You know, we haven't given out that percentage. I would say if you went back to history at the beginning of 2023, when we had the three and three, remember, we had comprehensive, which back in our, at that time, was 75% of our portfolio. We introduced a three and three, and I want to say in 18 months, it was then our biggest selling product. And it is still the three and three, which is the comprehensive with three refinements. I would say the NOAA product will give a run for its money on that, over time. I mean, as Joe said, doctors have to have the clinical confidence to be able to treat these cases, be able to finish and maybe no refinements or one refinement, but it's just how doctors want to buy. It's like all of us. Sometimes you buy a service plan up front on a product, and sometimes you don't, and these are doctors who want to pay for the service as they need to going forward.
Joseph Hogan, CEO
There's a lot of questions on this, Mike, and I think I'll just add one other thing, too, that I never liked when we were, you know, five AAs or whatever, is the economics of the orthodontists at that point in time aren't in line with ours. And so there's a perfectionism in this industry. We'll say, well, I'm going to try another liner. Maybe I'll just, you know, close that diastema a little bit more. This puts the economics of the doctors in line with our economics, too, and I think that's really healthy for both ends, of course.
Mike Sarkone, Analyst — Jefferies
Okay. And then, you know, you mentioned the updated guidance implies, you know, maybe low single-digit growth for clear aligners. And, you know, as we look to 2027, is that low single-digit growth like a good jumping-off point for the year? Or I guess how do we think about that as we look to the next year?
John Morici, CFO
Well, we haven't guided, and our plan would be to get through the fourth quarter and give a good update to that. But, again, you know, we'll reflect what the market is, and there's a reality of that. But you'll also see us reflect what we are doing within the market, some of the products that we talked about, some of the financing, other things that we're doing to help grow. I would say this, on iTero, the expectation is some of the changes that we have and some of the pricing and mix that we've seen, that's stabilized. We talked about that in the third quarter, and that's the expectation that we have such that we can build off of that into next year.
Joseph Hogan, CEO
You know, just on iTero, too, I mean, obviously, you know, the year's been a difficult, but this is the best scanner in the world overall, and it's well-positioned in both restorative and also on the orthodontic side, too. It's just we want to make sure that we, again, create options out there that allow us to penetrate different parts of the marketplace and to continue to open up the marketplace for us, too.
Mike Sarkone, Analyst — Jefferies
And I do, I have more questions. I want to double-click on iTero, but I did want to ask, you know, we are getting a bunch of questions on China, VBB. So I wanted to give you a chance to give your thoughts on how that may impact you guys.
Joseph Hogan, CEO
When you ask that question, I go back. We've been doing this dance for four years now. You know, the VPP is coming from an orthodontic standpoint. And every year we take it seriously, and we take it seriously this year, too. We always start with the 85% of our business in China is private, and that means it's Tier 1, Tier 2 hospitals also. We're not in many Tier 3, 2, 4. We have a completely self-contained business in China with manufacturing, with treatment planning and all those areas. So we're treated as a Chinese company in that kind of piece. So we feel good about our ability to compete in the BBP environment. We've positioned products properly that you have to do in order to address that. We don't know if it's coming or not. There's no certainty to it. But, you know, we've watched the implant business very closely and know that. It will expand the overall, I think, velocity of aligners in that country if that goes through. And we think we could benefit from that. At the same time, if it doesn't, we feel confident about our position in China, too. John, what would you add?
John Morici, CFO
And, you know, from the overall standpoint, China's less than 10% of our overall revenue, and ASP is much lower than our average, sub $1,000. So we've been able to position our portfolio even before VBP. I mean, the market really was dictating lower price, you know, a lot of these, you know, not as many refinements in some cases, moderate cases, maybe some light cases. So the market has already kind of pushed, in many cases, that portfolio down from a pricing standpoint that we've experienced over time and being able to operate within that. So as Joe said, we're in China for China as the costs will change, and we're reflecting that both in the manufacturing side as well as how we would have to go to market to be able to offset that. And when we think about our overall framework for 2027, it's in our thoughts as we've thought about this.
Mike Sarkone, Analyst — Jefferies
And is it fair to assume, you know, given, Joe, you mentioned this would. Probably grow penetration of aligners in China. There will be some price offsets to that. Is the thought that the volume more than offsets?
John Morici, CFO
You certainly get the volume benefit. I mean, there's an overall price pressure that we would see in this, but we're way underpenetrated in this market. When you think about clear aligners in China, it's less than 10% of the market. So we're coming from a position of we want to get a higher penetration. We want people to be able to experience Invisalign within China. So we've got that on the private side. We'd love to see this on the public side. We want to participate in this because it gives us the opportunity to grow the business, but you want to be there in the future to be able to help with growing the overall market share within. So it's a positioning that we want to be a part of. It's something that, you know, it works well for us there. And our portfolio and the way we're set up from an operating standpoint really sustains that.
Mike Sarkone, Analyst — Jefferies
Okay, great. And my last one on that would just be when we do get guidance for 27, you'll give us kind of more of the underlying assumptions around volume and price.
John Morici, CFO
We'll give you more about that. They give the details. We have talked about the 100 basis point improvement for next year. And that includes the overall framework that we're talking about when we talk about with China and so on. Because really, as Joe said, you're looking at maybe a second-half impact to this. It's a very small part of our business to start. You get some volume benefit, and the margin is a minimal impact for next year.
Mike Sarkone, Analyst — Jefferies
Okay, awesome. And then moving to scanners, you've been talking pretty consistently about volumes being very healthy. I guess, can you elaborate on that? What are the drivers of the pretty? Healthy volume growth that you're seeing, and then, you know, are there different pockets of demand geographically?
Joseph Hogan, CEO
Yeah, I think you kind of break the market up to restorative and the orthodontic marketplace. You know, we have good, strong penetration with iTero across the orthodontic markets across the world. Now, they do add more scanners per chair, and we work that piece, but overall, our penetration is really strong there. So you've seen us move more toward general dentistry from a restorative standpoint, and also labs, and obviously service those pieces, too. A big improvement in the sense of the way you can scan, you can do, you know, upper mouth, you know, we have a really wide coverage in that scanner for pallets, so if you have two or three implants at one time, you can take one scan and do those three implants like no other scanner in the world can, and so labs recognize this, and general dentists recognize this, too, so we feel good about, we're very underpenetrated in that restorative piece, and iTero has a fit there. At the same time, we'll continue to work hard on the orthodontic side. We'd love to see a scanner per chair, obviously, in an orthodontic office. And orthodontists would like to have that, too. And our price points are more amenable to that also. So we'll continue to focus on all three of those areas.
Mike Sarkone, Analyst — Jefferies
And then, you know, talking about double-digit scanner install-based growth, how do you think about the sustainability, right? You talked about being underpenetrated in general and resto, but also the opportunity to get maybe a scanner at each chair on the ortho side. So I guess can you speak to the sustainability of that double-digit install base growth?
Joseph Hogan, CEO
Yeah, I think, you know, when we developed the platform for Lumini Taro, it's not a mirror-based system. It's not confocal imaging. Those are the two predominant platforms that are out there. We developed that platform because we could do a lot of iterations from it. So there's a way to take cost out of that platform. There's a way to make it more specific to certain types of restorative and orthodontic procedures. And you'll see us work on that. We're not announcing anything today, but that's a platform we'll continue to enhance and allow us to be more competitive in the marketplace. Okay, great.
Mike Sarkone, Analyst — Jefferies
And, you know, talking about pricing appearing to stabilize, you mentioned that for 3Q. It sounds like per your commentary around, you know, 4Q. Trends when you guided, like that's a trajectory that continued into the fourth quarter. Is there any reason why price wouldn't remain stable as we head into 2027, or is that a reasonable assumption?
John Morici, CFO
On a like-for-like, we would expect pricing to be stable. You do get doctors who maybe they don't want a full system. They want to have the laptop version, and that's just a lower ASP product. And where you also do see some really coming down to the economics. Some doctors, they might have bought in the past, and now they want to lease or they want to rent them. And that's what we see in a lot of markets, like a China, like a Brazil, already. That's kind of gone to that already. In the Western world, you're just seeing that play out. U.S., it's become more, and you're seeing that in parts of Europe as well. So, again, they want to use the scanner. We want to see that come. Now, that is going to be leased revenue that you're going to get in the future. So maybe it displaces it in that current period, but you get the benefit later. But on a like-for-like, we don't expect to see too much of a change there. It's just a matter of the mixed shift that they might want to have.
Mike Sarkone, Analyst — Jefferies
Do you think this business can return to growth on a sales basis in 2027? The expectation is that it does.
John Morici, CFO
It might not grow as fast as Invisalign. We usually say that they go about equal. So we'll see how that plays out. It really comes down to, you know, kind of the capital equipment market and what doctors are feeling like in their practices and so on. But we're properly positioned there, as Joe said, with the type of scanner that we need. There'll be iterations to the scanner to get upgrades and others that those doctors might want. And we want to find different ways for those doctors to use our equipment, and iTero's a great platform for that, whether it's the product configuration or leasing and rental options that they might have.
Mike Sarkone, Analyst — Jefferies
Okay, great. I did want to, you know, shift gears again. You mentioned 100 BIPs of adjusted operating margin expansion in 2027, which is a great target. Can you talk about the key drivers there and maybe how that breaks up between, you know, gross margin and operating?
John Morici, CFO
The expectation is that it'll be a little bit more balanced between gross margin and op margin. This year, it's been mostly on the gross margin. It starts with some of the product configuration that we're talking about. When we don't have refinements, the gross margin on a product like that, much higher than if you have to do a lot of refinements and fulfilling this later. So product configuration is helping. Lower refinements, better gross margin. You see that in a large part of our portfolio. You see also, too, some of the restructuring that we've talked about our last couple years are really starting to play off. And so what you have is, you know, where we had a lot of manufacturing in places like Mexico, some of that manufacturer has now moved to China to really help with AIPAC. Some of it's gone to Poland to help here in Europe. And you see us, you know, talking about having expansion in places like India, where right now it's being serviced out of Mexico. And there's a lot of freight, a lot of duties, a lot of extra costs to get there. And it's a very high-growth market for us. So now to be there, it pretty much drives productivity on day one. So you get those benefits. So some of that productivity is just around programs, getting closer to our customers, as you know. And that's why we haven't had as much of some of the headwinds this year. Even though freight has been more expensive, all companies are seeing higher fuel prices. Fortunately for us, getting closer to our customers, we reduced the amount of air freight. You reduced the amount of trucking costs and so on. And that's really helped us. So some of it's product-related. Some of it's just related to the structure that we have from our overall cost savings. And we think that's very durable. I think as you go into next year, some of the go-to-market activities that we have to really drive productivity, looking at layers, looking at span of control, looking at things to be able to help drive some of that OPEC savings as well, we think that leverage will sustain into next year and feel good about how we're positioned.
Mike Sarkone, Analyst — Jefferies
Okay, and I guess can you talk about, we have a somewhat challenged consumer that we talked about. Does that, is that the assumption that's baked into that 100 bps margin expansion? It's, the assumption is that no change, really, for the consumer.
Joseph Hogan, CEO
Yeah, we're not economists. We're just going to run this thing until it changes.
John Morici, CFO
But it's similar type of consumer, but things that we're doing to be able to help unlock that. You know, consumer who's maybe more cautious.
Mike Sarkone, Analyst — Jefferies
So in a scenario where we did see a consumer recovery, presumably that could be some decent upside?
John Morici, CFO
We'd like to see more of those months. You see Michigan Index or other indices that you use, but you want to start seeing more of that trend. But we know that, you know, our product, it's somewhat discretionary, maybe not a lot of reimbursement. And if you can get some of those overall consumer to be a little bit more, you know, The feeling like they want to go into treatment, that's a good thing for us.
Joseph Hogan, CEO
Stronger consumer is a good thing.
Mike Sarkone, Analyst — Jefferies
And then, you know, you did also mention another 3Q call, the Invisalign Sports Guard. Can you just talk about, you know, the revenue opportunity there and the strategic rationale behind that?
Joseph Hogan, CEO
That's a derivative of our 3D printing technology overall. So what we do is we use the same printing machines out of Austria, Cubicure machines, different viscosity resin. And if you look at the sports guard marketplace, it's about $6 billion to $8 billion, depending on how. And it goes back to when I played sports. It's still primarily boil and bite, right? They're uncomfortable. People take them out of their mouths. What this allows you to do is to tailor make a mouth guard for someone much more comfortable than it could be before. The properties are 40% less material needed for the same impact resistance. We can take a lingual cut out in the back so a person playing sports can actually talk to their teammates, right, and breathe better during that piece. Our channel's really good. Orthodontists love this channel because they can get into the teen segments in their particular zip codes, scan those patients from mouth guards, but also use that as an adjacency to be able to move on to tooth treatment overall. So it's just a natural brand extension for this business, and it's a natural extension of the technology that we've developed through 3D printing.
John Morici, CFO
So when you think about it, it's added revenue that we don't have, so that's great, and we'll start to build on that. We're seeing a lot of demand from doctors who want this as part of their practice because, as Joe said, not only is it added revenue for all of us, but it's a lead generator. Now you can have doctors, ortho or GP, that can scan, you know, the kids on a football team or, you know, other parts of sports where they can get some access to those potential, you know, teens or preteens and being able to then show their parents what their treatment would look like. And so it's a natural evolution. It's based on our technology that we have, the direct fabrication, and we're really excited about it. We're getting a lot of pull from our doctors to really want this to be part of their portfolio, so we're encouraged by those early results.
Joseph Hogan, CEO
And you said, what could it be? Our retainer business is the half a billion dollars, right? And when you look at the size of this marketplace, you look at the channels we run it through, there's no reason it can't be in that kind of a range overall from what we can see. All right.
Mike Sarkone, Analyst — Jefferies
And we only have a little bit of time left, so, Joe, I figured maybe we'll give you an opportunity to close out the session with your message to the investment community.
Joseph Hogan, CEO
Well, overall, as I leave a line, I leave with a lot of confidence in Jen Davis, as I mentioned before. And I've been working with Jen now for 40 days or so. I love the insight, curiosity, and experience that she has, and I think I grew up in GE, and at GE, you got to see great leaders, right? You saw different businesses at different times. It was just almost like a university to be able to grow up and to really learn business. I see the same thing with Jennifer from her P&G days, the same kind of questions. She's been around great leaders in her life. She's gotten to do that. So it gives me so much confidence in being able to hand off this business, to hand it off to someone with that kind of experience. At the same time, I could not be more excited about a line. I wish I was 50, okay, and I could stay another 10 years. I really believe in this business. I love this business. The 3D printing piece will revolutionize this industry. You haven't asked a lot of questions about that, but we put a lot of money into this, and it'll change it. When you, overall, when you can change the geometry of these aligners for different forces at different times, you'll speed and accelerate the timing of these. We'll look at maybe possibly nighttime wear rather than 20, 18-hour wear that we have today. And you can just, you can combine so many things that cost us money today when you put on, you know, if you have tabs or you have mandular advancement and those kind of things. It could all be done in one shot at one time. And then back to iTero, the best scanner in the world, best platform, and we'll work that, too. So I leave here with a lot of confidence in the business and a huge amount of confidence in Jen taking over.
Mike Sarkone, Analyst — Jefferies
Awesome. Well, we really appreciate your insight and your time. So, Joe, John, thank you very much for being up here with us.
Joseph Hogan, CEO
Thank you.